Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKITQE)

Drug Name
Amoxapine Drug Info
Synonyms
Amoxan; Amoxapina; Amoxapinum; Amoxepine; Ascendin; Asendin; Asendis; Defanyl; Demolox; Desmethylloxapin; Desmethylloxapine; Moxadil; CL 67772; A-129; Amoxapina [INN-Spanish]; Amoxapinum [INN-Latin]; Asendin (TN); Asendis (TN); CL-67772; Defanyl (TN); Demolox (TN); KS-1197; Moxadil (TN); CL-67,772; Amoxapine (JP15/USP/INN); Amoxapine [USAN:BAN:INN:JAN]; 2-Chlor-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepin; 2-Chloro-11-(1-piperazinyl)-dibenz[b,f][1,4]oxazepine; 2-Chloro-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepine; 2-Chloro-11-(1-piperazinyl)dibenz[b,f][1,4]oxazepine; 2-chloro-11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazepine; 2-chloro-11-piperazin-1-yldibenzo[b,f][1,4]oxazepine; 8-chloro-6-piperazin-1-ylbenzo[b][1,4]benzoxazepine
Indication
Disease Entry ICD 11 Status REF
Major depressive disorder 6A70.3 Approved [1]
Therapeutic Class
Antidepressants
Cross-matching ID
PubChem CID
2170
ChEBI ID
CHEBI:2675
CAS Number
CAS 14028-44-5
TTD Drug ID
DMKITQE
VARIDT Drug ID
DR01091
INTEDE Drug ID
DR0103
ACDINA Drug ID
D00034

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Norepinephrine transporter (NET)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [6]
Amitriptyline DMK7F9S Depression 6A70-6A7Z Approved [7]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [8]
Desipramine DMT2FDC Attention deficit hyperactivity disorder 6A05.Z Approved [6]
Cocaine DMSOX7I Anaesthesia 9A78.6 Approved [9]
Bupropion DM5PCS7 Depression 6A70-6A7Z Approved [10]
Tapentadol hydrochloride DMXLSH3 Acute pain MG31 Approved [11]
Venlafaxine DMR6QH0 Anxiety disorder 6B00-6B0Z Approved [10]
Trimipramine DM1SC8M Major depressive disorder 6A70.3 Approved [12]
Duloxetine DM9BI7M Depression 6A70-6A7Z Approved [13]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [14]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [15]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [16]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [17]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [18]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [19]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [20]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [21]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [22]
Propranolol DM79NTF Angina pectoris BA40 Approved [23]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Prolactin (PRL)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Verapamil DMA7PEW Angina pectoris BA40 Approved [24]
Ranitidine DM0GUSX Gastric ulcer DA60 Approved [25]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [26]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [27]
Methotrexate DM2TEOL Anterior urethra cancer Approved [28]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [29]
Naloxone DM3FXMA Narcotic depression 6A7Z Approved [30]
Aripiprazole DM3NUMH Bipolar I disorder Approved [31]
Fluoxetine DM3PD2C Bipolar depression Approved [32]
Penicillamine DM40EF6 Cystinuria 5C60.2 Approved [33]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Eplerenone DMF0NQR Heart failure BD10-BD13 Approved [34]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [35]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [36]
Voriconazole DMAOL2S Aspergillosis 1F20 Approved [37]
Proguanil DMBL79I Malaria 1F40-1F45 Approved [38]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [38]
Loratadine DMF3AN7 Allergy 4A80-4A85 Approved [39]
Nelfinavir mesylate DMFX6G8 N. A. N. A. Approved [40]
Capsaicin DMGMF6V Back pain ME84.Z Approved [41]
Axitinib DMGVH6N Renal cell carcinoma 2C90 Approved [42]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Norepinephrine transporter (NET) TTAWNKZ SC6A2_HUMAN Inhibitor [2]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6) Main DME DECB0K3 CP2D6_HUMAN Substrate [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Biotransformations [4]
Prolactin (PRL) OTWFQGX7 PRL_HUMAN Gene/Protein Processing [5]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 201).
2 Effects of acute and chronic treatment with amoxapine and cericlamine on the sleep-wakefulness cycle in the rat. Neuropharmacology. 1994 Aug;33(8):1017-25.
3 Addition of amoxapine improves positive and negative symptoms in a patient with schizophrenia. Ther Adv Psychopharmacol. 2013 Dec;3(6):340-2.
4 In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine. Biopharm Drug Dispos. 2011 Oct;32(7):398-407.
5 Double-blind comparison of amoxapine and imipramine in the treatment of depressed patients. J Clin Psychiatry. 1984 Feb;45(2):54-56, 57-9.
6 Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
7 Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
8 Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
9 Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
10 Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
11 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
12 Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
13 Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
14 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
15 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
16 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
17 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
18 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
19 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
20 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
21 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
22 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
23 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
24 Verapamil-induced hyperprolactinemia complicated by a pituitary incidentaloma. Ann Pharmacother. 1995 Oct;29(10):999-1001. doi: 10.1177/106002809502901009.
25 [Impotence and gynecomastia secondary to hyperprolactinemia induced by ranitidine]. Therapie. 1994 Jul-Aug;49(4):361-2.
26 Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol Cell Endocrinol. 2005 Jul 15;239(1-2):27-36. doi: 10.1016/j.mce.2005.04.008.
27 Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease. Brain. 2009 Feb;132(Pt 2):392-401. doi: 10.1093/brain/awn326. Epub 2009 Jan 19.
28 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
29 The effect of thioridazine on prolactinoma growth in a schizophrenic man: case report. Gen Hosp Psychiatry. 1985 Oct;7(4):364-6. doi: 10.1016/0163-8343(85)90053-2.
30 Influence of naloxone on muscle sympathetic nerve activity, systemic and calf haemodynamics and ambulatory blood pressure after exercise in mild essential hypertension. J Hypertens. 1995 Apr;13(4):447-61.
31 The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials. J Affect Disord. 2009 May;115(1-2):18-26. doi: 10.1016/j.jad.2008.12.017. Epub 2009 Feb 23.
32 Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. J Clin Psychiatry. 2006 Jun;67(6):952-7. doi: 10.4088/jcp.v67n0612.
33 Massive breast enlargement in a patient receiving D-penicillamine for systemic sclerosis. J Rheumatol. 1985 Oct;12(5):990-1.
34 The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
35 Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
36 Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
37 The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
38 Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
39 Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
40 Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
41 Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
42 Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.